Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 16 citing articles:

Local consolidative therapy in oligometastatic non-small-cell lung cancer after effective systemic treatment: who will benefit?
Jiayi Deng, Mingyi Yang, Qing Zhou
Cancer Biology and Medicine (2025), pp. 1-7
Open Access | Times Cited: 1
The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study
Min Ouyang, Hao Sun, Xiaoyu Liu, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Impacto dos inibidores de checkpoint imunológico em câncer de pulmão não pequenas células – Revisão Sistemática
Maria Juliana Mendonça Da Silva, Arlete Fernandes, Vládia Teles Moreira, et al.
Journal of Medical and Biosciences Research. (2025) Vol. 2, Iss. 1, pp. 182-193
Closed Access
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
Shuang Dong, Xiaoyu Li, Qing Huang, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101215-101215
Closed Access
Safety and Efficacy of Radiotherapy Combined With Sintilimab in Advanced NSCLC Patients Who Progressed on First or Second Line Therapy: A Prospective, Multiple Center, and Single‐Arm Study
Xiaoyi Feng, Xiaoping Xiao, Hui Guan, et al.
Thoracic Cancer (2025) Vol. 16, Iss. 6
Open Access
Effect and safety of immunotherapy among elder patients (age ≥ 65) with recurrent or metastatic nasopharyngeal carcinoma
Ruiling Xie, Wu-Lin Cai, Yan‐Feng Ouyang, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Clinical and dynamic circulating cytokines profile features of long-term progression-free survival benefit to immune checkpoint inhibitors in advanced non–small cell lung cancer
Jia‐Yi Deng, Ming Gao, Xue Fan, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 6
Open Access
Clinical characteristics and survival outcomes of long-term responders for advanced nonsmall cell lung cancer patients with first-line PD-1/PD-L1 inhibitors: a multicenter retrospective study
Zhijuan Du, Xiangwei Ge, Li Yao, et al.
Postgraduate Medical Journal (2025)
Closed Access
The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer
Qian Zhu, Hao Hu, Li-Ying OuYang, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
The association of PD-L1 expression status and PD-1/PD-L1 inhibitors-related toxicities profile in non-small cell lung cancer
Qian Zhu, Hao Hu, Li-Ying OuYang, et al.
Research Square (Research Square) (2025)
Closed Access
Meta-analysis of the efficacy and safety of sintilimab in combination with chemotherapy for advanced non-small cell lung cancer
Liling Pan, Qiongqing Chen, Liang Ning-sheng, et al.
Current Therapeutic Research (2025), pp. 100796-100796
Open Access
Comparative efficacy of six programmed cell death Protein-1 inhibitors as first-line treatment for advanced non-small cell lung cancer: a multicenter retrospective cohort study
Siyuan Chen, Tao Li, Wenyu Yang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review
Jia Zhou, Chuan-Peng Wang, Jun Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Patterns of failure and the subsequent treatment after progression on first-line immunotherapy monotherapy in advanced non-small cell lung cancer: a retrospective study
Jia‐Yi Deng, Mingyi Yang, Xiaorong Yang, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Lung squamous cell carcinoma with metastases in the left atrium and left ventricle responds to treatment with immunotherapy: A case report
Yulei Shen, Yumin Zheng, Zhening Liu, et al.
Oncology Letters (2024) Vol. 29, Iss. 2
Open Access | Times Cited: 1
WITHDRAWN: AID-SLR: A Generative Artificial Intelligence-Driven Automated System for Systematic Literature Review
Kyeryoung Lee, Surabhi Datta, Hunki Paek, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Adjuvant chemoradiotherapy plus PD-1 inhibitor for pN3 gastric cancer: a randomized, multicenter, Phase III trial
Yang Wang, Menglong Zhou, Guichao Li, et al.
Future Oncology (2024), pp. 1-8
Closed Access
[TIM3+CD8+ T Cell Expression and Clinical Significance in the Central and Non-central Tumor Microenvironment of Non-small Cell Lung Cancer].
Jia-juan Wu, Shiying Guo, Lei-lei Lv, et al.
PubMed (2024) Vol. 27, Iss. 12, pp. 903-910
Closed Access
Page 1

Scroll to top